Jan Walewski
About
In The Last Decade
Jan Walewski
200 papers receiving 6.9k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Pathology and Forensic Medicine 4.6k
- Oncology 4.2k
- Genetics 1.9k
- Neurology 1.4k
- Immunology 913
Countries citing papers authored by Jan Walewski
This map shows the geographic impact of Jan Walewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Walewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Walewski more than expected).
Fields of papers citing papers by Jan Walewski
This network shows the impact of papers produced by Jan Walewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Walewski. The network helps show where Jan Walewski may publish in the future.
Co-authorship network of co-authors of Jan Walewski
This figure shows the co-authorship network connecting the top 25 collaborators of Jan Walewski. A scholar is included among the top collaborators of Jan Walewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Walewski. Jan Walewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 7 | |
| 5 | 7 | |
| 6 | 2 | |
| 7 | TG-1701 A selective bruton tyrosine kinase (btk) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (u2) in chronic lymphocytic leukemia (cll) and lymphoma | 1 |
| 8 | 0 | |
| 9 | 18 | |
| 10 | 2 | |
| 11 | 9 | |
| 12 | Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study breakdown → | 386 |
| 13 | Early and late follow-up of patients with Hodgkin’s lymphoma. Recommendations of the Polish Lymphoma Research Group | 1 |
| 14 | IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY | 2 |
| 15 | 9 | |
| 16 | 77 | |
| 17 | R-CHOP VERSUS R-FC FOLLOWED BY MAINTENANCE WITH RITUXIMAB OR IFN: FIRST RESULTS OF A RANDOMIZED TRIAL FOR ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA | 4 |
| 18 | 287 | |
| 19 | Randomised controlled trial of ABVD vs. two multi-drug regimens (MDRs) for advanced Hodgkin's lymphoma (HL): Initial results of UKLG LY09 (ISRCTN97144519). | 1 |
| 20 | An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma. | 34 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.